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ABSTRACT
A prospective randomized blinded study was conducted on 12 clinically healthy adult dogs of both sexes 
(mean weight of 18.34 ± 0.78 kg) divided into three groups (n = 4). The animals received 0.4 mg/kg midazolam 
and 10 μg/kg dexmedetomidine (group A), 0.4 mg/kg midazolam and 20 μg/kg dexmedetomidine (group B) 
and 0.4 mg/kg midazolam + 20 μg/kg dexmedetomidine + 4 μg/kg fentanyl (group C) intramuscularly, using 
separate syringes. Ten minutes later Ketamine was administered intravenously in all the groups. A signiﬁ  cantly 
(P<0.05) shorter weak time (onset of sedation) and down time (onset of recumbency) were recorded in animals 
in group C as compared to the animals of groups A and B. Muscle relaxation was excellent in group C. The 
pedal reﬂ  ex was abolished up to 30 min in groups A and B and up to 60 min in group C. Intubation was only 
possible in groups B and C. The anaesthetic induction dose of ketamine was minimal in group C. Standing 
recovery time was shortest in the animals of group C. Respiratory rate (RR) decreased signiﬁ  cantly (P<0.05) 
throughout the observation period, but rectal temperature (RT) decreased signiﬁ  cantly (P<0.05) towards the 
end of the observation period in all the groups. Heart rate decreased signiﬁ  cantly (P<0.05) in the animals 
of group B. Mean arterial pressure (MAP) was maintained within the physiological range in all the groups. 
It was concluded that dexmedetomidine (10 μg/kg)-midazolam-ketamine can produce anaesthesia for about 
20 min in dogs. Increasing the dose of dexmedetomidine did not enhance the duration of anaesthesia, but the 
further addition of fentanyl not only reduced the induction dose of ketamine but also increased the duration of 
anaesthesia up to 50 min. Dexmedetomidine-midazolam-fentanyl-ketamine can be used for prolonged duration 
of injectable anaesthesia in dogs. 
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Introduction
Alpha-2 adrenoceptor agonists are frequently used as pre-anaesthetics in veterinary 
practice. Dexmedetomidine is a highly selective and potent 2-adrenoceptor agonist that 
offers sedative and analgesic beneﬁ  ts over racemic medetomidine (KUUSELA et al., 2000). 
Co-administration of alpha-2 adrenoceptor agonists with opioids or benzodiazepines may 
result in pronounced sedation and analgesia (MUIR, 1998). Midazolam, a benzodiazepine 
derivative, is used as a premedicant, sedative and an anaesthetic induction agent, with 
minimal effect on cardiac function (LEMKE, 2007). Fentanyl citrate, a highly potent 
synthetic μ agonist, rapidly crosses the blood-brain barrier, which is responsible for its 
characteristic rapid onset and short duration of action (HUG and MURPHY, 1979). Opioids 
like butorphanol, hydromorphone, and buprenorphine, have been recommended for use 
in combination with dexmedetomidine and ketamine in dogs and cats (KO et al., 2009). 
A recent study suggested that dexmedetomidine-ketamine-buprenorphine was a suitable 
injectable anaesthesia combination for castration in dogs (BARLETTA et al., 2011). A 
review of the literature did not show any published report on evaluation of midazolam-
dexmedetomidine-ketamine with fentanyl for anaesthesia in dogs. However, the 
combination of fentanyl-dexmedetomidine-midazolam resulted in excellent analgesia, 
sedation and muscle relaxation with favourable conditions for intubation in dogs (AHMAD 
et al., 2011). As small animal practitioners commonly use injectable anaesthetics alone or 
with inhalation anaesthetics for short-duration surgical procedures, it is worthwhile to 
investigate the use of dexmedetomidine-ketamine-opioid-based anaesthetic combinations 
for this purpose (BARLETTA et al., 2011). The present study was therefore designed to 
compare dexmedetomidine-midazolam-ketamine with dexmedetomidine-midazolam-
fentanyl-ketamine for injectable anaesthesia in dogs.
Materials and methods
A prospective randomized blinded study was conducted on 12 client-owned, mixed 
breed adult dogs of either sex weighing 18.34 ± 0.78 kg. An informed consent was obtained 
from the owners prior to subjecting the animals to the study. The animals were deemed 
healthy through physical examination, complete blood count, estimation of plasma urea 
and creatinine, and recording of electrocardiogram. 
Design of work. The dogs were divided randomly into three equal groups, designated 
as group A, B and C. In the animals of group A, dexmedetomidine (Dexdomitor; 0.5 mg/
mL; Orion Pharma, Turku, Finland) 10 μg/kg and midazolam (Mezolam; 1 mg/mL; Neon 
Laboratories, Thane, India) 0.4 mg/kg were administered simultaneously in the thigh 
muscles using separate syringes. In the animals of group B, dexmedetomidine 20 μg/
kg and midazolam 0.4 mg/kg were administered in the same manner as in group A. In 
the animals of group C dexmedetomidine 20 μg/kg, midazolam 0.4 mg/kg and fentanyl 511 Vet. arhiv 83 (5), 509-523, 2013
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(Fendrop; 50 mcg/mL; Sun Pharmaceuticals India Ltd., India) 4 μg/kg were administered 
in the thigh muscles using separate syringes. Ten minutes later, ketamine (Ketmin 50; 
50 mg/mL; Themis Medicare Ltd., Uttarakhand, India) was administered i.v. until the 
abolition of pedal reﬂ  ex in all the groups.
Base values for different parameters were recorded before administration of pre-
anaesthetic drugs. After administration of pre-anaesthetic drugs, the animal was left loose 
in a room to allow onset of the effects of the drugs and to record weak time (onset of 
sedation) and down time (onset of recumbency). Ten minutes later the animal was secured 
on the examination table in right lateral recumbency, and ketamine was administered in 
the cephalic vein until onset of anaesthesia was achieved, which was conﬁ  rmed by loss 
of pedal reﬂ  ex. 
Clinical observations. Weak time was recorded as the time elapsed from the time 
of injection of pre-anaesthetic drugs to the time of onset of in-coordination / ataxia or 
drowsiness. Down time was recorded as the time that elapsed from the time of injection 
of pre-anaesthetic drugs to the time when the animal attained sternal recumbency.
Relaxation of the jaw was taken as a measure of muscle relaxation. It was evaluated 
by observing the resistance to opening of the jaws while pulling the jaws apart. The status 
of jaw relaxation was recorded at 0 min (base value), 10 min (just before administration 
of ketamine) and then at 15, 20, 30, 45, 60, 75, 90, 105 and 120 min on a 0 to 4 score 
scale, as shown in Table 1. At each interval, the mean value for jaw relaxation score was 
calculated and the muscle relaxation was graded as nil if the mean score was 0, very mild 
when the score was >0 but <1, mild when the score was ≥1 but <2, moderate when the 
score was ≥2 but <3 and excellent when the score was 3.
Status of palpebral reﬂ  ex was recorded, at the same interval as for the relaxation of 
the jaw, by observing blink of the eye lids on touching the area around medial canthus of 
the eyes with an index ﬁ  nger, on a 0 to 3 score scale (Table 1). 
The status of pedal reﬂ  ex was recorded as a measure of the depth of analgesia. It was 
assessed by observing the withdrawal reﬂ  ex to pinching the interdigital skin of the hind 
foot of the animal (KUUSELA, 2004). The response of the animal to pinching was graded 
on a 0 to 3 score scale (Table 1) at the same interval as for the jaw relaxation. The mean 
value for pedal reﬂ  ex score was calculated and the analgesia was graded at each interval 
as: no analgesia if the mean score was 0, very mild analgesia when the score was >0 but 
<1, mild analgesia when the score was ≥1 but <2, moderate analgesia when the score was 
≥2 but <3, and complete analgesia when the score was 3. 
Response to intubation was recorded to assess the status of laryngeal reﬂ  exes and 
feasibility of intubation during different stages of sedation/anaesthesia in all the animals. 
The response to intubation was recorded by attempting intubation, at the same intervals 512 Vet. arhiv 83 (5), 509-523, 2013
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as for the jaw relaxation, until the animal allowed easy intubation using a 0 to 4 score 
scale (Table 1). The mean value for intubation score was calculated at each interval and 
the status of laryngeal reﬂ  ex was graded as: strong if the mean score was <1, very mild 
depression when the score was ≥1 but <2, mild depression when the score was ≥2 but <3, 
moderate depression when the score was ≥3 but <4, and complete depression of laryngeal 
reﬂ  ex when the score was 4. Extent of salivation was recorded at different intervals as for 
the other reﬂ  exes and was graded from 0 to 3 using the score scale shown in Table 1. The 
reﬂ  ex responses were allotted by a person blinded to the treatment.
Table 1. System of recording of various reﬂ  exes and responses (Adapted and modiﬁ  ed after 
AMARPAL et al., 1996)
 Parameter   Parameter 
Score (Numbers) Score (Numbers)
0 0 1 1 2 2 3 3 4 4
Relaxation  Relaxation 
of jaw of jaw
Not allowing to  Not allowing to 
open the jaws open the jaws
Resistant to  Resistant to 
opening the  opening the 
jaws and closed  jaws and closed 
quickly quickly
Less resistance  Less resistance 
to opening the  to opening the 
jaws and closed  jaws and closed 
slowly slowly
No resistance  No resistance 
and jaws remain  and jaws remain 
open open
 _  _
Palpebral  Palpebral 
reﬂ  ex reﬂ  ex
Intact and  Intact and 
strong (quick  strong (quick 
blink) blink)
Intact but weak  Intact but weak 
(slow response) (slow response)
Very weak  Very weak 
(very slow  (very slow 
and occasional  and occasional 
response) response)
Abolished Abolished
(no response)  (no response) 
 _  _
Pedal reﬂ  ex Pedal reﬂ  ex
Intact and  Intact and 
strong (strong  strong (strong 
withdrawal) withdrawal)
Intact but  Intact but 
weak (animal  weak (animal 
responding  responding 
slowly) slowly)
Intact but very  Intact but very 
light (slow  light (slow 
and occasional  and occasional 
response) response)
Abolished  Abolished 
completely (no  completely (no 
response) response)
_ _
Response to  Response to 
intubation  intubation 
Not permitting  Not permitting 
entry of tube in  entry of tube in 
the mouth the mouth
Allowing entry  Allowing entry 
but chewing but chewing
Allowing  Allowing 
deeper entry but  deeper entry but 
coughing coughing
Difﬁ  cult  Difﬁ  cult 
intubation with  intubation with 
coughing coughing
Easy  Easy 
intubation  intubation 
without  without 
coughing coughing
Recovery time was recorded as the time elapsed from injection of the drugs to the 
time of reappearance of pedal reﬂ  ex. The time to the return of righting reﬂ  ex was recorded 
as the time from injection of drug until the animal regained sternal recumbency. Standing 
recovery time was recorded as the time interval elapsed from the time of injection of the 
drugs until the time when animal attained standing position. Complete recovery time was 
recorded as the time elapsed from the time of reappearance of pedal reﬂ  ex to the time 
when the animal stood and walked unassisted. Duration of anaesthesia was recorded as 
the time interval that elapsed from the time of abolition of pedal reﬂ  ex to the time of 
reappearance of the pedal reﬂ  ex. 
The total dose of ketamine required to induce anaesthesia was recorded and dose per 
kg body mass was calculated for each group. 513 Vet. arhiv 83 (5), 509-523, 2013
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Physiological observations. Heart rate (HR), respiratory rate (RR), rectal temperature 
(RT), oxygen saturation (SpO2) and mean arterial pressure (MAP) were recorded before 
administration of the drug(s) at 0 min (base value) and at 10 min (just before administration 
of ketamine) and then at 15, 20, 30, 45, 60, 75, 90, 105, and 120 min after administration 
of the drugs. Respiratory rate was recorded by counting the excursions of thoraco-
abdomen. Rectal temperature was recorded with the help of a digital thermometer, as per 
the standard procedure. Heart rate (HR) and oxygen saturation (SpO2) were measured 
by means of a pulse oximeter (Model 8600, pulse oximeter; Nonin Medical Inc. MPLS, 
Minnesota) applied to the toe web of the forelimb after clipping the hair around the site 
and cleaning with 70% alcohol (HUSS et al., 1995). Mean arterial pressure was recorded 
by applying the cuff of a non-invasive blood pressure (NIBP) (Surgivet®, Smith’s medical 
PM, Inc. Waukesha, USA) monitor around the digital artery.
Statistical analysis. The data were analysed for statistical signiﬁ  cance using SPSS 
software, version 15.0 (SPSS, Inc., Chicago, Illinois). The means at different time intervals 
were compared among different groups, using one way analysis of variance and Duncan’s 
multiple range test (DMRT). The mean values at different intervals were compared with 
their base values in each group using the Paired “t” test. The subjective data generated 
from the scoring of various parameters were analysed using the Kruskal Wallis test. In 
each analysis, the differences were considered signiﬁ  cant at a value of P<0.05. 
Results
Clinical observations. Weak time was signiﬁ  cantly (P<0.05) shorter in the animals of 
group C (2.25 ± 0.25 min) as compared to group B (3.25 ± 0.25 min) and group A (4.37 
± 0.23 min). Down time in the animals of group C (4.00 ± 0.40 min) was signiﬁ  cantly 
(P<0.05) shorter than that in group A (5.87 ± 0.125 min), but did not differ signiﬁ  cantly 
from that in group B (4.50 ± 0.28 min) (Fig. 1).
Excellent muscle relaxation was observed up to 30 min in groups A and B, and up to 
90 min in group C. Muscle relaxation score was signiﬁ  cantly (P<0.05) higher in group 
C as compared to groups A and B from the 45 to 90 min observation periods. Palpebral 
reﬂ  ex was more sluggish in the animals of groups A and C as compared to group B 
(Fig. 2). The pedal reﬂ  ex was lost completely after the administration of ketamine at 10 
min in animals in all the groups, which indicated onset of surgical anaesthesia (score 3). 
The pedal reﬂ  ex was lost completely up to 30 min in groups A and B and up to 60 min 
in group C (Fig. 3) suggesting anaesthesia of 20 min (time of ketamine injection to 30 
min) in groups A and B and 50 min (time of ketamine injection to 60 min) in group C. 
Intubation was not possible in the animals of group A at any time interval of the study. 
Easy intubation was possible in the animals of groups B and C, and loss of laryngeal 
reﬂ  ex persisted up to the 45 min interval in group B and 90 min in group C (Fig. 4). 514 Vet. arhiv 83 (5), 509-523, 2013
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Intubation scores were signiﬁ  cantly higher (P<0.05) in group C 45 to 90 min interval. 
Mild to moderate salivation was observed in animals of all the groups.
Fig. 1. Mean weak time, down time, righting reﬂ  ex time, standing recovery time and complete 
recovery time in groups A (dexmedetomidine 10 μg/kg-midazolam 0.4 mg/kg-ketamine), B 
(dexmedetomidine 20 μg/kg-midazolam 0.4 mg/kg-ketamine) and C (dexmedetomidine 20 μg/
kg-midazolam 0.4 mg/kg-Fentanyl 4 μg/kg-ketamine)
Fig. 2. Mean ± SE palpebral reﬂ  ex score after drug administration in groups A (dexmedetomidine 
10 μg/kg-midazolam 0.4 mg/kg-ketamine), B (dexmedetomidine 20 μg/kg-midazolam 0.4 mg/kg-
ketamine) and C (dexmedetomidine 20 μg/kg-midazolam 0.4 mg/kg-Fentanyl 4 μg/kg-ketamine) 
at different time intervals515 Vet. arhiv 83 (5), 509-523, 2013
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Fig. 3. Mean ± SE pedal reﬂ  ex score after drug administration in groups A (dexmedetomidine 10 
μg/kg-midazolam 0.4 mg/kg-ketamine), B (dexmedetomidine 20 μg/kg-midazolam 0.4 mg/kg-
ketamine) and C (dexmedetomidine 20 μg/kg-midazolam 0.4 mg/kg-Fentanyl 4 μg/kg-ketamine) 
at different time intervals
Fig. 4. Mean ± SE intubation score after drug administration in groups A (dexmedetomidine 10 
μg/kg-midazolam 0.4 mg/kg-ketamine), B (dexmedetomidine 20 μg/kg-midazolam 0.4 mg/kg-
ketamine) and C (dexmedetomidine 20 μg/kg-midazolam 0.4 mg/kg-Fentanyl 4 μg/kg-ketamine) 
at different time intervals516 Vet. arhiv 83 (5), 509-523, 2013
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The dose of ketamine needed for induction of anaesthesia was reduced from 9.04 ± 
0.0.59 mg/kg in group A to 8.93 ± 0.83 mg/kg in group B and 7.98 ± 0.22 mg/kg in group C. 
Recovery time was signiﬁ  cantly (P<0.05) shorter in the animals of group A (51.75 
± 4.49 min) as compared to group B (74.50 ± 5.42 min) and group C (83.75 ± 3.44 
min). The time to the return of righting reﬂ  ex in group B (146.50 ± 10.33 min) was 
signiﬁ  cantly (P<0.05) longer than that in group A (123.25 ± 2.28 min) and C (126.25 
± 3.7 min). Standing recovery time was shortest in the animals of group C (142.00 ± 
6.62 min) followed, in increasing order, by group A (148.50 ± 5.51 min) and in group 
B (158.75 ± 10.71 min), but the differences between the groups were not signiﬁ  cant. 
The complete recovery time was longer in the animals of group B (173.00 ± 10.07 
min) than that in group C (162.00 ± 6.28 min) and in group A (160.50 ± 3.92 min). The 
differences in the complete recovery time between the groups were not signiﬁ  cant (Fig. 1). 
Table 2. Mean ± SE of heart rate in the animals of groups A (dexmedetomidine 10 μg/kg-
midazolam 0.4 mg/kg-ketamine), B (dexmedetomidine 20 μg/kg-midazolam 0.4 mg/kg-ketamine) 
and C (dexmedetomidine 20 μg/kg-midazolam 0.4 mg/kg-Fentanyl 4 μg/kg-ketamine) at different 
time intervals
Groups Intervals (Min)
0 1 01 52 03 04 56 07 59 0 1 0 5 1 2 0
Group 
A
101.00 
 ± 12.65
66.50a 
 ± 14.97
107.00 
 ± 22.18
83.50 
 ± 9.84
86.50 
 ± 7.29
75.25 
 ± 10.29
73.25a 
 ± 8.66
65.20 
 ± 8.13
68.25 
 ± 7.89
69.50a 
 ± 6.03
76.50a 
 ± 3.00
Group 
B
105.50 
 ± 8.14
48.75a 
 ± 9.10
93.00 
 ± 13.41
88.50 
 ± 11.90
77.00 
 ± 8.82
56.75* 
 ± 9.10
43.75b** 
 ± 1.37
41.25** 
 ± 1.75
44.25* 
 ± 4.55
40.00b** 
 ± 1.15
41.75b** 
 ± 2.50
Group 
C
115.00 
 ± 15.5 
109.50b 
 ± 15.26
111.75 
 ± 3.35
95.00 
 ± 11.09 
90.00 
 ± 12.51
62.00 
 ± 4.88
56.25ab 
 ± 7.12
48.75 
 ± 9.09
46.25 
 ± 9.28
54.00ab 
 ± 6.55
56.25b* 
 ± 8.50
*Signiﬁ  cantly different from base value (P<0.05); **Signiﬁ  cantly different from base value (P<0.01); Values  *Signiﬁ  cantly different from base value (P<0.05); **Signiﬁ  cantly different from base value (P<0.01); Values 
with different alphabets differ signiﬁ  cantly at respective intervals (P<0.05) with different alphabets differ signiﬁ  cantly at respective intervals (P<0.05)
Physiological observations. In animals of group A, heart rate remained decreased 
throughout the study period, although this decrease was not signiﬁ  cant as compared to 
the baseline value. In animals of group B, heart rate decreased signiﬁ  cantly (P<0.01) 
at the 10 min interval i.e. just before the administration of ketamine. HR showed some 
improvement from 10 min to 30 min after administration of ketamine, however, the 
values were still lower as compared to the base value. At 45 min interval HR was again 
signiﬁ  cantly (P<0.05) lower than the base value and remained so up to 120 min of the 
study (P<0.01). In animals of group C, heart rate decreased and remained below the 
baseline throughout the study period but this decrease was signiﬁ  cant (P<0.05) only at 
120 min. Mean heart rate was signiﬁ  cantly (P<0.05) lower in group B at 60, 105 and 120 
min, when compared to group A (Table 2). 517 Vet. arhiv 83 (5), 509-523, 2013
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Table 3. Mean ± SE of respiratory rate in the animals of groups A (dexmedetomidine 10 μg/kg-
midazolam 0.4 mg/kg-ketamine), B (dexmedetomidine 20 μg/kg-midazolam 0.4 mg/kg-ketamine) 
and C (dexmedetomidine 20 μg/kg-midazolam 0.4 mg/kg-Fentanyl 4 μg/kg-ketamine) at different 
time intervals
Groups Groups
Intervals (Min) Intervals (Min)
0 0 10 10 15 15 20 20 30 30 45 45 60 60 75 75 90 90 105 105 120 120
Group  Group 
A A
33.50  33.50 
 ± 7.54  ± 7.54
16.00 16.00* *   
 ± 2.65  ± 2.65
14.25  14.25 
 ± 0.85  ± 0.85
14.00  14.00 
 ± 1.35  ± 1.35
15.00 15.00* *   
 ± 1.78  ± 1.78
14.70 14.70* *   
 ± 2.50  ± 2.50
14.75 14.75* *   
 ± 3.00  ± 3.00
15.00 15.00* *   
 ± 2.65  ± 2.65
15.00 15.00* *   
 ± 3.37  ± 3.37
15.50 15.50* *   
 ± 4.25  ± 4.25
21.50 21.50* *   
 ± 8.75  ± 8.75
Group  Group 
B B
34.50  34.50 
 ± 5.04  ± 5.04
13.25 13.25* *   
 ± 0.75  ± 0.75
12.25 12.25* *   
 ± 0.63  ± 0.63
11.50 11.50* *   
 ± 0.96  ± 0.96
11.25 11.25* *   
 ± 0.85  ± 0.85
10.50 10.50* *   
 ± 1.20  ± 1.20
10.50 10.50* *   
 ± 1.20  ± 1.20
10.50 10.50* *   
 ± 1.20  ± 1.20
11.25 11.25* *   
 ± 0 .95  ± 0 .95
10.50 10.50* *   
 ± 0.65  ± 0.65
11.00 11.00* *   
 ± 1.08  ± 1.08
Group  Group 
C C
26.00  26.00 
 ± 3.03  ± 3.03
11.00 11.00* *   
 ± 0.41  ± 0.41
11.75 11.75* *   
 ± 1.18  ± 1.18
11.00 11.00* *   
 ± 0.82  ± 0.82
12.25 12.25* *   
 ± 1.25  ± 1.25
11.50 11.50* *   
 ± 1.20  ± 1.20
15.00 15.00* *   
 ± 1.47  ± 1.47
16.00 16.00* *   
 ± 0.71  ± 0.71
16.50 16.50* *   
 ± 0.96  ± 0.96
17.25 17.25* *   
 ± 0.63  ± 0.63
19.25 19.25* *   
 ± 1.32  ± 1.32
*Signiﬁ  cantly different from base value (P<0.05); **Signiﬁ  cantly different from base value (P<0.01); Values  *Signiﬁ  cantly different from base value (P<0.05); **Signiﬁ  cantly different from base value (P<0.01); Values 
with different alphabets differ signiﬁ  cantly at respective intervals (P<0.05) with different alphabets differ signiﬁ  cantly at respective intervals (P<0.05)
Table 4. Mean ± SE of rectal temperature in the animals of groups A (dexmedetomidine 10 μg/kg-
midazolam 0.4 mg/kg-ketamine), B (dexmedetomidine 20 μg/kg-midazolam 0.4 mg/kg-ketamine) 
and C (dexmedetomidine 20 μg/kg-midazolam 0.4 mg/kg-Fentanyl 4 μg/kg-ketamine) at different 
time intervals
 Groups  Groups
Intervals (Min) Intervals (Min)
0 0 10 10 15 15 20 20 30 30 45 45 60 60 75 75 90 90 105 105 120 120
Group  Group 
A A
38.59 38.59
 ± 0.12  ± 0.12
38.77  38.77 
 ± 0.19  ± 0.19
38.48  38.48 
 ± 0.41  ± 0.41
38.41  38.41 
 ± 0.38  ± 0.38
38.15 38.15
 ± 0.37  ± 0.37
37.95  37.95 
 ± 0.38  ± 0.38
37.70  37.70 
 ± 0.43  ± 0.43
37.57 37.57* *   
 ± 0.42  ± 0.42
37.40 37.40* *   
 ± 0.40  ± 0.40
37.21 37.21* *   
 ± 0.39  ± 0.39
37.65 37.65* *   
 ± 0.39  ± 0.39
Group  Group 
B B
38.99  38.99 
 ± 1.19  ± 1.19
39.03 39.03* *   
 ± 0.14  ± 0.14
38.93 38.93** **   
 ± 0.12  ± 0.12
38.66  38.66 
 ± 0.15  ± 0.15
38.56  38.56 
 ± 0.13  ± 0.13
38.40  38.40 
 ± 0.12  ± 0.12
38.24  38.24 
 ± 0.09  ± 0.09
37.86  37.86 
 ± 0.20  ± 0.20
37.73  37.73 
 ± 0.22  ± 0.22
37.56  37.56 
 ± 0.22  ± 0.22
37.43  37.43 
 ± 0.22  ± 0.22
Group  Group 
C C
38.98  38.98 
 ± 0.08  ± 0.08
38.78  38.78 
 ± 0.07  ± 0.07
38.75  38.75 
 ± 0.06  ± 0.06
38.61 38.61* *   
 ± 0.09  ± 0.09
38.52 38.52* *   
 ± 0.08  ± 0.08
38.43 38.43* *   
 ± 0.09  ± 0.09
38.21 38.21* *   
 ± 0.15  ± 0.15
37.91 37.91* *   
 ± 0.15  ± 0.15
37.87 37.87** **   
 ± 0.08  ± 0.08
37.56 37.56** **   
 ± 0.05  ± 0.05
37.59 37.59** **   
 ± 0.03  ± 0.03
*Signiﬁ  cantly different from base value (P<0.05); **Signiﬁ  cantly different from base value (P<0.01) *Signiﬁ  cantly different from base value (P<0.05); **Signiﬁ  cantly different from base value (P<0.01)518 Vet. arhiv 83 (5), 509-523, 2013
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Table 5. Mean ± SE of mean arterial pressure in the animals of groups A (dexmedetomidine 10 
μg/kg-midazolam 0.4 mg/kg-ketamine), B (dexmedetomidine 20 μg/kg-midazolam 0.4 mg/kg-
ketamine) and C (dexmedetomidine 20 μg/kg-midazolam 0.4 mg/kg-Fentanyl 4 μg/kg-ketamine) 
at different time intervals
Groups Groups
Interval (Min) Interval (Min)
0 0 10 10 15 15 20 20 30 30 45 45 60 60 75 75 90 90 105 105 120 120
Group  Group 
A A
116.75  116.75 
 ± 6.70  ± 6.70
118.25  118.25 
 ± 8.22  ± 8.22
117.75  117.75 
 ± 11.56  ± 11.56
119.80  119.80 
 ± 12.37  ± 12.37
120.50  120.50 
 ± 10.31  ± 10.31
122.00 122.00
 ± 10.54  ± 10.54
106.25 106.25* *   
 ± 8.73  ± 8.73
111.25  111.25 
 ± 10.88  ± 10.88
105.00 105.00** **   
 ± 5.87  ± 5.87
107.25  107.25 
 ± 8.13  ± 8.13
110.50 110.50
 ± 9.04  ± 9.04
Group  Group 
B B
128.25  128.25 
 ± 8.37  ± 8.37
113.07  113.07 
 ± 15.25  ± 15.25
157.00  157.00 
 ± 9.84  ± 9.84
160.00 160.00* *   
 ± 14.42  ± 14.42
131.00  131.00 
 ± 4.69  ± 4.69
131.50  131.50 
 ± 8.79  ± 8.79
114.42  114.42 
 ± 4.09  ± 4.09
111.50 111.50
 ± 1.65  ± 1.65
121.50  121.50 
 ± 6.53  ± 6.53
118.25  118.25 
 ± 9.49  ± 9.49
120.50 120.50
 ± 5.17  ± 5.17
Group  Group 
C C
124.75  124.75 
 ± 8.90  ± 8.90
138.75  138.75 
 ± 3.40  ± 3.40
152.75  152.75 
 ± 4.93  ± 4.93
162.50  162.50 
 ± 10.47  ± 10.47
144.75  144.75 
 ± 4.11  ± 4.11
124.75  124.75 
 ± 7.20  ± 7.20
120.75  120.75 
 ± 3.81  ± 3.81
111.25  111.25 
 ± 6.10  ± 6.10
106.75  106.75 
 ± 3.92  ± 3.92
102.75  102.75 
 ± 1.18  ± 1.18
110.50 110.50
 ± 3.08  ± 3.08
*Signiﬁ  cantly different from base value (P<0.05); **Signiﬁ  cantly different from base value (P<0.01) *Signiﬁ  cantly different from base value (P<0.05); **Signiﬁ  cantly different from base value (P<0.01)
RR decreased signiﬁ  cantly (P<0.05) as compared to the respective baseline values 
in all the groups. Comparison of RR between the groups did not reveal any signiﬁ  cant 
difference at any time interval (Table 3).
RT increased initially up to 15 min in the animals of group B (P<0.05). Thereafter RT 
decreased gradually and remained just below the base line throughout the study period. In 
the animals of groups A and C, RT decreased gradually to become signiﬁ  cantly (P<0.05) 
below the baseline from 75 to 120 min in group A and from 20 min to 120 min in group 
C (Table 4). However, RT did not differ signiﬁ  cantly between the groups. 
Oxygen saturation values did not differ signiﬁ  cantly (P>0.05) from the baseline value 
throughout the study period, except for occasional decreases in groups B and C up to the 
45 min interval.
Mean arterial pressure (MAP) increased initially and then decreased gradually towards 
the end of study in all the groups. In group A, mean arterial pressure reached signiﬁ  cantly 
below the baseline at the 60 min (P<0.05) and 90 min (P<0.01) intervals. Mean arterial 
pressure remained near the baseline values throughout the study period in the animals of 
group B, except at 20 min, where a signiﬁ  cant (P<0.05) increase was observed. MAP in 
the group C animals ﬂ  uctuated around baseline values without signiﬁ  cant changes (Table 
5). MAP did not differ signiﬁ  cantly between the groups.
Discussion
Dexmedetomidine, like medetomidine, has rapid onset of action owing to its lipophilic 
properties (AMARPAL et al., 1996). The fast onset of sedation and recumbency recorded 519 Vet. arhiv 83 (5), 509-523, 2013
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in the present study conformed to the observations made in earlier studies following the 
administration of medetomidine/dexmedetomidine (AMARPAL et al., 1996; AHMAD et al., 2011).
Ketamine, when used alone for anaesthesia in dogs, produces spontaneous movement, 
muscle rigidity and violent recovery (LIN, 2007). Clinically it is used in combination with 
or after tranquilizers or sedatives to eliminate its side effects. In the present study, 20 μg/
kg dose of dexmedetomidine with fentanyl and midazolam as pre-anaesthetics to ketamine 
produced better muscle relaxation for a longer duration, as compared 10 and 20 μg/kg 
dose of dexmedetomidine with midazolam. The ﬁ  ndings of the present study conformed 
to the observations of earlier researchers, who reported greater muscle relaxation when 
dexmedetomidine or medetomidine was combined with opioid and/or ketamine in cats or 
dogs (KO et al., 2000; SELMI et al., 2003).
Abolition of palpebral reﬂ  ex was more consistent in group C as compared to group 
B. The lower palpebral reﬂ  ex score recorded in the animals of group B, as compared 
to group A, could be attributable to α1-adrenergic receptor activation mediated arousal 
and vigilance due to the increased dose of dexmedetomidine (PUUMALA et al., 1997). 
It has been reported that α1- adrenoceptor effect will predominate with increased dose 
of α-2 agonists, which can antagonize the hypnotic action of even potent α-2 agonists 
like dexmedetomidine (SINCLAIR, 2003). The greater depression of the palpebral reﬂ  ex 
in the animals of group C as compared group B might be attributed to the action of 
fentanyl. Fentanyl, basically an analgesic agent, could have increased the depth of the 
sedation by its synergistic interaction with dexmedetomidine/midazolam. Synergistic 
interactions have been reported between alpha-2 agonists, opioids and benzodiazepines 
(SALMENPERA et al., 1994; AMARPAL et al., 1996; BOL et al., 2000).
Analgesia was excellent, with complete loss of pedal reﬂ  ex, in all the groups after 10 
min but persisted for longer in the animals of group C. Complete loss of pedal reﬂ  ex was 
plausibly attributed to the action of ketamine in all the groups. Ketamine itself is a short 
acting anaesthetic drug, but its relatively long duration of anaesthesia in the present study 
could be attributable to the action of dexmedetomidine/gmidazolam administered as pre-
anaesthetics in groups A and B. The further increased duration of anaesthesia in group C 
could be attributed to the additional action of the μ opioid agonist, fentanyl. A synergistic 
interaction between alpha-2 agonists, opioids and benzodiazepines has been reported in 
earlier studies (SALMENPERA et al., 1994; AMARPAL et al., 1996; BOL et al., 2000).
Dexmedetomidine and midazolam, by themselves, are not general anaesthetics 
and are incapable of completely abolishing the laryngeal reﬂ  ex, and also laryngeal and 
pharyngeal reﬂ  exes are reasonably well maintained during ketamine induced anaesthesia 
in all species (HASKINS et al., 1975). This might have prevented intubation in group A. 
Increase in the dose of dexmedetomidine might have led to further depression of laryngeal 
reﬂ  exes to allow intubation in the animals of group B. In group C, the complete and 520 Vet. arhiv 83 (5), 509-523, 2013
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prolonged depression of laryngeal reﬂ  ex might have been achieved due to the synergistic 
interaction of dexmedetomidine and midazolam with fentanyl (SALMENPERA et al., 1994).
Recovery from ketamine anaesthesia occurs through tissue redistribution and hepatic 
metabolism of the drug making it a short acting anaesthetic drug (STEPHENSON et al., 
1978). However, the higher dose of dexmedetomidine in group B and group C, resulting 
in deeper sedation, might have led to reduced metabolic activity to delay redistribution 
and metabolism of the drugs, resulting in prolongation of recovery time (JACOBSON and 
HARTSFIELD, 1993; KO et al., 2000).
The total dose of ketamine required to induce anaesthesia was minimal in group C, 
but the differences in groups A and B were marginal. It suggested that increasing the 
dose of dexmedetomidine has no dose sparing effect on ketamine, but further addition of 
fentanyl can reduce the dose of the anaesthetic agent.
Bradycardia was observed in all the groups, but it was more obvious in groups B 
and C. Dexmedetomidine, like medetomidine, causes dose dependent depression of 
the cardiovascular system, with maximal depression at a higher dose (KUUSELA et al., 
2001). Fentanyl may also cause bradycardia by activation of cardiac vagal efferents 
(THURMON et al., 1999). The greater decrease in HR recorded in the animals of groups B 
and C could thus be attributable to the higher dose of dexmedetomidine in group B and 
dexmedetomidine plus fentanyl in group C.
Alpha-2 agonists are known to induce RR depression, which is mediated by activation 
of the alpha-2 adrenergic pathway, leading to inhibition of locus coeruleus neurons 
(OYAMADA et al., 1998). Similarly, μ receptors agonists induce analgesia, accompanied 
by some respiratory depression, but in therapeutic doses fentanyl has minimal side effects 
(THURMON et al., 1999). Respiratory rates decreased markedly in all the three groups. 
Profound respiratory depression has been reported when medetomidine and ketamine 
were used in dogs by KO et al. (2001).
Sedative/anaesthetic drugs may plausibly induce a decrease in rectal temperature by 
decreasing heat production, as a result of decreased muscular activity, and by direct action 
on the hypothalamus (VIRTANEN, 1989). In spite of the decrease in last phase of the study, 
RT remained within physiological limits in all the groups, and differences in RT were not 
signiﬁ  cant among the groups. 
Low pulse oximeter readings are indicative of reduced arterial oxygenation 
and diminished tissue perfusion. However, as reported by LEPPANEN et al. (2006) 
vasoconstriction may also lead to low pulse oximeter readings. A decrease in oxygen 
saturation after the administration of dexmedetomidine in humans and swine has been 
reported by SANO et al. (2010). However, in the present study Spo2 was fairly maintained, 521 Vet. arhiv 83 (5), 509-523, 2013
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except slightly lower oximeter readings at a few intervals in groups B and C, which could 
be attributable to vasoconstriction due to the higher dose of dexmedetomidine.
Mean arterial blood pressure increased initially as compared to baseline values, 
which was followed by a decrease towards the end of the study period in all the groups. 
Dexmedetomidine/medetomidine has been associated with high systemic vascular 
resistance due to alpha-2 mediated vasoconstriction, which maintains arterial blood 
pressure in the face of lowered cardiac output (LAWRENCE et al., 1996). In the present 
study blood pressure was also maintained within the physiological limits in all the groups, 
which could be attributable to the effect of dexmedetomidine and ketamine. 
Conclusion
It was concluded that dexmedetomidine (10 μg/kg)-midazolam-ketamine induces 
surgical anaesthesia for 20 min in dogs. Increasing the dose of dexmedetomidine did not 
enhance the depth and duration of anaesthesia but further addition of fentanyl not only 
reduced the induction dose of ketamine but also increased the duration of anaesthesia. 
The combination may be suitable for injectable anaesthesia in dogs.
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SAŽETAK
Poduzeto je prospektivno istraživanje na 12 slučajno odabranih klinički zdravih pasa i kuja (prosječne 
tjelesne mase 18,34 ± 0,78 kg) podijeljenih u tri skupine (n = 4). Životinjama skupine A bio je intramuskularno 
primijenjen midazolam u dozi od 0,4 mg/kg i deksmedetomidin u dozi od 10 μg/kg. Životinjama skupine B bio 
je i/m primijenjen midazolam u dozi od 0,4 mg/kg i deksmedetomidin 20 μg/kg, a životinje skupine C primile 
su i/m 0,4 mg/kg midazolama, 20 μg/kg deksmedetomidina i 4 μg/kg fentanila. Deset minuta nakon toga svim 
je životinjama intravenski bio ubrizgan ketamin. Značajno (P<0,05) kraće vrijeme smirivanja (nastup sedacije) 
i vrijeme lijeganja ustanovljeno je u životinja skupine C u usporedbi sa skupinama A i B. Opuštanje mišićja bilo 
je izvrsno u skupini C. Nožni reﬂ  eks nestao je nakon 30 minuta u skupinama A i B, a nakon 60 minuta u skupini 
C. Intubacija je bila moguća samo u životinja skupine B i C. Doza ketamina potrebna za početak anestezije 
bila je najmanja u životinja skupine C. Vrijeme potrebno za ponovno ustajanje bilo je najkraće u životinja 
skupine C. Frekvencija disanja značajno se smanjila (P<0,05) u čitavom razdoblju promatranja, dok se rektalna 
temperatura u svih životinja značajno smanjila (P<0,05) na kraju razdoblja promatranja. Frekvencija bila znatno 
se smanjila (P<0,05) u životinja skupine B. Srednji arterijski tlak bio je u ﬁ  ziološkim granicama u svih životinja. 
Može se zaključiti da kombinacija deksmedetomidin (10 μg/kg)-midazolam-ketamin može u pasa dovesti 
do anestezije za oko 20 minuta. Povećanje doze deksmedetomidina nije povećalo trajanje anestezije. Ipak, 
daljnja primjena fentanila ne samo da je smanjila početnu dozu ketamina već je povećala trajanje anestezije 
na 50 minuta. Deksmedetomidin-midazolam-fentanil-ketamin mogu se rabiti za produženo trajanje injekcijske 
anestezije u pasa.
Ključne riječ: anestezija, deksmedetomidin, fentanil, ketamin, midazolam, psi  ________________________________________________________________________________________.